跳至主要内容
临床试验/NCT01563770
NCT01563770Unknown不适用

A Double Blind, Randomized Placebo-controlled Cross-over Study on the Cardiovascular Effects of Salvia Miltiorrhiza Extract (Danshen) in Patients With Hypertension and Hyperlipidemia.

Radboud University Medical Center2 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2012年4月最近更新:
适应症

试验速览

阶段
不适用
入组人数
20
试验地点
2
主要终点
Hyperlipidemia

研究概览

简要总结

Rationale: Extracts of the plant Salvia miltiorrhiza (Danshen) have been used as traditional Chinese medicine in the treatment of cardiovascular diseases, such as angina pectoris and myocardial infarction. Several preclinical studies point towards promising effects of Danshen on risk factors of atherosclerotic cardiovascular diseases, such as hyperlipidemia and hypertension.

Objective: Our primary objective is to determine the effect of Salvia miltiorrhiza extract (Danshen) on hyperlipidemia. Secondary objective is to investigate the effect of Danshen on hypertension. Further objectives are to determine its effect on endothelial function, oxidative stress, inflammation, hemostasis and hemorheology, and on insulin sensitivity.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
40 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age: 40-70
  • postmenopausal, or
  • use of contraceptive pill
  • Hyperlipidemia:
  • elevated level of triglycerides: > 1.7 mmol/L, or
  • elevated level of LDL-cholesterol: > 3.5 mmol/L
  • Hypertension:
  • systolic pressure > 140 mm Hg, or
  • diastolic pressure > 90 mm Hg
  • Signed informed consent

排除标准

  • Alcohol or drug abuse
  • History of cardiovascular disease (myocard infarct, angina pectoris, CVA)
  • Diabetes mellitus, when treated with insulin
  • Pregnancy
  • Hyperlipidemia which needs conventional treatment
  • elevated level of triglycerides: > 8 mmol/L
  • elevated level of LDL-cholesterol: > 5 mmol/L
  • Hypertension which needs conventional treatment:
  • systolic pressure > 180 mm Hg
  • diastolic pressure > 110 mm Hg
  • Clinically significant liver disease (3 times the upper normal limit of ALAT,ASAT)
  • Clinically significant anemia (male Hb < 6,9 mmol/L, female < 6,25 mmol/L)
  • Renal disease defined as MDRD < 60 ml/min/1.73m2
  • Participation to any drug-investigation during the previous 90 days
  • Use of any herbal product during the previous 30 days
  • Concomitant (chronic) use of:
  • Medicinal products:
  • ACE-inhibitors, including a.o. captopril, enalapril, ramipril
  • AT1-antagonists, including a.o. losartan, valsartan, irbesartan
  • Statins, including a.o. simvastatin, rosuvastatin
  • Anticoagulant drugs, including a.o. aspirin
  • Calciumantagonists (including a.o. amlodipine, nifedipine, verapamil)
  • Use of more than 1 antihypertensive drug
  • High-dose antihypertensive medication (above defined daily dose)
  • Drugs which are exclusively metabolised by CYP3A4 (Flockhart DA; P450 drug interaction table, including a.o. erythromycin, midazolam, cyclosporine, HIV antivirals)
  • Food products:
  • (Antioxidant) vitamin supplements
  • Other herbs, including a.o. St John's wort
  • Grapefruit juice

结局指标

主要结局

Hyperlipidemia

时间窗: after 4 weeks of treatment with Danshen

Blood tests: lipids, in particular LDL-cholesterol.

次要结局

  • Hypertension(after 4 weeks of treatment with Danshen)
  • Endothelial function(after 4 weeks of treatment with Danshen)
  • Plasma markers of oxidative stress(after 4 weeks of treatment with Danshen)
  • Vascular inflammation and inflammatory activation of adipose tissue(after 4 weeks of treatment with danshen)
  • Hemostasis and hemorheological parameters(after 4 weeks of treatment with Danshen)
  • Insulin sensitivity(after 4 weeks of treatment with Danshen)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验